Loading...
Loading...
VCYT| Name | Value |
|---|---|
| Revenues | 114.4M |
| Cost of Revenue | 38.6M |
| Gross Profit | 75.8M |
| Operating Expense | 71.1M |
| Operating I/L | 4.7M |
| Other Income/Expense | 2.8M |
| Interest Income | 2.7M |
| Pretax | 7.4M |
| Income Tax Expense | 1.6M |
| Net Income/Loss | 5.7M |
Veracyte, Inc. is a global diagnostics company specializing in genomic testing for cancer and lung diseases. The company's products, including Afirma Genomic Sequencing Classifier, Xpression Atlas, Decipher Prostate Biopsy, Prosigna Breast Cancer Assay, and Envisia Genomic Classifier, are used to accurately diagnose and inform treatment decisions for various cancers and lung diseases. Veracyte also offers technology licensing and collaboration arrangements with industry leaders. Its innovative tests help avoid unnecessary surgeries and guide personalized treatment, generating revenue through product sales and licensing agreements.
